European Central Bank leaders emphasize AI's role for competitive advantage amid inflation concerns, spotlighting soaring food prices impacting economic stability. Lagarde urges swift AI adoption.
Tesla faces a regulatory setback for Full Self-Driving system approval in Europe, while advancing AI chip development. Meanwhile, Volkswagen cuts costs in EV development efforts.
Beijing and Brazil collaborate on critical minerals to challenge US economic dominance, aiming to address China's rare earths dominance and bolster global trade relations.
Crypto market turmoil casts a shadow over US IPOs ahead of Thanksgiving 2025, leading to declining investor sentiment and concerns for upcoming listings amid heavy losses in recent crypto IPOs.
US-China leaders Trump and Xi discuss AI chip sales amid rising tensions, with potential impacts on tech trade, national security, and global diplomatic relations.
Brazil's record tax revenues of 262 billion reais in October highlight fiscal challenges as President Lula's administration grapples with primary deficits and political unrest amid Congress setbacks.
UBS faces pressure amid China's risky property market and impending Swiss banking regulations, potentially impacting its operations, investor confidence, and future strategy in Europe.
The European Central Bank aims to boost economic growth by integrating AI technologies, while tackling rising food and services inflation affecting lower-income households across the eurozone.
Gold prices near record highs and Nasdaq gains as traders anticipate Federal Reserve rate cuts in December, driven by economic data and tech stock innovation.
Brazil's 2026 inflation forecasts are revised amid record tax revenues and ongoing fiscal challenges. Rising government spending and deficits highlight economic pressures despite increased revenues.
Bitcoin's downturn affects US IPOs, with crypto-related firms facing 31% declines. Retail traders grapple with family discussions on investments during Thanksgiving 2025, amid market volatility.
Biogen teams up with Dayra Therapeutics, investing $50 million to develop macrocyclic peptides, aiming to revolutionize treatments for autoimmune diseases and expand its immunology research portfolio.